Lorrin Koran
Publication Details
-
Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder.
Compr Psychiatry. 2010 Jul-Aug; (4): 373-9
We hypothesized that subjects with obsessive-compulsive disorder (OCD) who received extended-release fluvoxamine (fluvoxamine ER) in a 12-week placebo-controlled trial would exhibit improvements in psychosocial domains of health-related quality of life (HRQOL) and that additional improvements would occur after a 40-week open-label extension trial. We also hypothesized that greater OCD symptom improvement in the first 12 weeks of treatment would be associated with greater HRQOL improvement after 52 weeks of treatment.
Help